Nyxoah SA (NYXH) is a promising global healthcare innovator that is dedicated to improving well-being and quality of life for people suffering from obstructive sleep apnea (OSA). The company is renowned for developing and introducing the Genio® system, the world’s first and only leadless, battery-free and minimally invasive neurostimulator implant, specifically created to combat OSA.
The company was founded in 2009 and has its corporate headquarters in Mont-Saint-Guibert, Belgium, while maintaining a presence in Australia and the United States as well. Nyxoah SA emphasizes a patient-centered approach, with a focused commitment to offering transformative treatment options for patients whose lives are significantly affected by the challenges of OSA.
The company's flagship Genio® system represents a pioneering leap in OSA treatment technology. The inventive system employs bilateral stimulation to the hypoglossal nerve, ensuring that a patient's airway remains constantly open while they sleep. Unlike other solutions on the market, it is a fully implantable device that is both battery-free and leadless, making it less intrusive and uncomfortable for patients. The device can be personalizing to each individual, ensuring patient-centric and efficient treatment.
In addition to its disruptive technological innovation, Nyxoah SA shows a strong commitment to clinical excellence. The company runs various studies to monitor and gather data on the long-term efficacy and safety of its Genio® system, with presented clinical results suggesting promising improvements in sleep, quality of life, and cardiovascular outcomes for OSA patients.
The company is led by a team of experienced and passionate professionals who have a strong track record in OSA focused medical device companies. CEO Olivier Taelman, joined by a diverse and internationally experienced executive management team, is steering the company towards fulfilling its mission of changing the lives of people who experience sleep apnea.
The shares of Nyxoah SA have been listed on the regulated market of Euronext Brussels since September 2020 under the symbol NYXH. This listing represents a significant milestone which enabled the company to broaden its shareholder base and secure the necessary funding to accelerate its commercial and technological development plans.
Overall, Nyxoah SA is more than just a medical technology company. It is a beacon of hope for OSA patients globally, consistently focused on delivering innovative, user-friendly, and effective treatment options for a disorder that compromises the quality of life of millions each year. Through its revolutionary products and clinical commitment, Nyxoah SA is undoubtedly paving the way for a profound transformation in sleep apnea care.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Nyxoah has implanted the first patient in its BREATHE study, a US post-approval trial for the Genio system used in obstructive sleep apnoea. This study aims to enroll up to 229 patients across various US clinical sites to assess the system's effectiveness and safety over five years. The trial will gather real-world evidence on the Genio system's performance in routine clinical practice, reinforcing Nyxoah's commitment to rigorous clinical evaluation.
Nyxoah initiated its U.S. post-approval BREATHE study with the first Genio system implant for obstructive sleep apnea, a significant step in expanding clinical evidence for its FDA-approved therapy. Despite this milestone, the company's shares dropped approximately 8% following the announcement, reflecting a year-to-date decline of 64.8%. The BREATHE study aims to generate long-term real-world evidence to support broader physician adoption, payer reimbursement, and commercialization of the Genio system.
Cantor Fitzgerald has reiterated its Overweight rating and $6.00 price target for Nyxoah SA following positive results from the company's U.S. clinical trial. The ACCCESS U.S. Pivotal Study met its primary endpoints, showing a 77.2% AHI respondent rate and no device-related serious adverse events, keeping Nyxoah on track for regulatory submission in late Q3 or early Q4 2026. Despite a stock decline over the past year, the firm maintains confidence in Nyxoah's label expansion prospects, while the company also reported significant Q2 revenue growth.
Nyxoah (NYXH) stock rose after the Belgian MedTech company announced positive trial results for its Genio system in patients with Complete Concentric Collapse (CCC) of the soft palate. The company plans to seek a label expansion for its sleep therapy device based on these results.
Nyxoah SA has issued a regulatory announcement regarding its total number of voting rights and shares following the issuance of 1,767,402 new shares on August 20, 2026. This issuance was related to a contribution in kind from the holder of convertible bonds. The company details its current share capital, total voting rights, unissued subscription rights, and potential voting rights upon conversion of outstanding convertible bonds.